DK Life Science Statistics

Total Valuation

DK Life Science has a market cap or net worth of KRW 122.98 billion. The enterprise value is 153.30 billion.

Market Cap	122.98B
Enterprise Value	153.30B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

DK Life Science has 31.98 million shares outstanding. The number of shares has decreased by -17.34% in one year.

Current Share Class	31.98M
Shares Outstanding	31.98M
Shares Change (YoY)	-17.34%
Shares Change (QoQ)	+0.52%
Owned by Insiders (%)	13.69%
Owned by Institutions (%)	n/a
Float	10.60M

Valuation Ratios

The trailing PE ratio is 10.11.

PE Ratio	10.11
Forward PE	n/a
PS Ratio	0.94
PB Ratio	0.94
P/TBV Ratio	0.98
P/FCF Ratio	n/a
P/OCF Ratio	61.36
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.90, with an EV/FCF ratio of -31.69.

EV / Earnings	22.78
EV / Sales	1.17
EV / EBITDA	7.90
EV / EBIT	11.76
EV / FCF	-31.69

Financial Position

The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.29.

Current Ratio	1.80
Quick Ratio	1.30
Debt / Equity	0.29
Debt / EBITDA	1.97
Debt / FCF	-7.91
Interest Coverage	8.14

Financial Efficiency

Return on equity (ROE) is 5.68% and return on invested capital (ROIC) is 5.09%.

Return on Equity (ROE)	5.68%
Return on Assets (ROA)	4.02%
Return on Invested Capital (ROIC)	5.09%
Return on Capital Employed (ROCE)	9.59%
Revenue Per Employee	1.31B
Profits Per Employee	67.29M
Employee Count	100
Asset Turnover	0.65
Inventory Turnover	2.49

Taxes

In the past 12 months, DK Life Science has paid 3.65 billion in taxes.

Income Tax	3.65B
Effective Tax Rate	35.15%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	3,867.50
200-Day Moving Average	n/a
Relative Strength Index (RSI)	52.61
Average Volume (20 Days)	151,104

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, DK Life Science had revenue of KRW 131.17 billion and earned 6.73 billion in profits. Earnings per share was 380.45.

Revenue	131.17B
Gross Profit	32.98B
Operating Income	13.03B
Pretax Income	10.38B
Net Income	6.73B
EBITDA	19.41B
EBIT	13.03B
Earnings Per Share (EPS)	380.45

Full Income Statement

Balance Sheet

The company has 7.93 billion in cash and 38.25 billion in debt, giving a net cash position of -30.32 billion or -948.05 per share.

Cash & Cash Equivalents	7.93B
Total Debt	38.25B
Net Cash	-30.32B
Net Cash Per Share	-948.05
Equity (Book Value)	130.46B
Book Value Per Share	4,057.86
Working Capital	57.98B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.00 billion and capital expenditures -6.84 billion, giving a free cash flow of -4.84 billion.

Operating Cash Flow	2.00B
Capital Expenditures	-6.84B
Free Cash Flow	-4.84B
FCF Per Share	-151.24

Full Cash Flow Statement

Margins

Gross margin is 25.14%, with operating and profit margins of 9.94% and 5.13%.

Gross Margin	25.14%
Operating Margin	9.94%
Pretax Margin	7.91%
Profit Margin	5.13%
EBITDA Margin	14.80%
EBIT Margin	9.94%
FCF Margin	n/a

Dividends & Yields

DK Life Science does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	17.34%
Shareholder Yield	17.34%
Earnings Yield	5.47%
FCF Yield	-3.93%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on August 7, 2025. It was a forward split with a ratio of 2.

Last Split Date	Aug 7, 2025
Split Type	Forward
Split Ratio	2

Scores

DK Life Science has an Altman Z-Score of 2.62 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.62
Piotroski F-Score	6